Sherif, M. M., H. S. El-Abhar, H. M. Fawzy, A. M. Gad, and D. M. Abdallah, "Repurposing the antimalarial chloroquine: a potential therapy for hepatic injury in a rat model of hindlimb ischemia–reperfusion by modulating apoptosis, autophagy, inflammation, and oxidative stress", Future Journal of Pharmaceutical Sciences , vol. 11, 2025.
Selim, H. M. R. M., A. A. El-Gazar, D. M. Abdallah, H. B. Abo-Zalam, G. M. Ragab, A. N. Abdallah, R. A. El-Gazar, S. Alshehri, E. M. Yousef, R. Ballal, et al., "Parthanatos drives cognitive decline in repeated brain trauma: MSC-derived exosomes as a novel therapeutic strategy", Front Pharmacol , vol. 16, 2025.
Hamed, A. B., I. M. Fawzy, D. M. Abdallah, Y. S. Abulfadl, K. A. Ahmed, and H. S. El-Abhar, "GPER1 Mediates Hippocampal Therapeutic Effect of Prunetin in Uremic Encephalopathy: Modulation of the RUNX2 Axis, TLR4 Cascade, Necroptosis, and Mitochondrial Dysfunction", Arch Pharm (Weinheim), vol. 358(9), 2025.
Mohamed, O. E., D. M. Abdallah, A. M. Fayez, R. A. Mohamed, and H. S. El-Abhar, "Morin post-treatment surpassed calpeptin in ameliorating 3-NP-induced cortical neurotoxicity via modulation of glutamate/calpain axis, Kidins220, and BDNF/TrkB/AKT/CREB trajectory", Int Immunopharmacol ., vol. 116, pp. 109771, 2023.
El-Emam, M. A., E. Sheta, H. S. El-Abhar, D. M. Abdallah, A. E. M. Kerdawy, W. M. Eldehna, and M. A. Gowayed, "Morin suppresses mTORc1/IRE-1α/JNK and IP3R-VDAC-1 pathways: Crucial mechanisms in apoptosis and mitophagy inhibition in experimental Huntington's disease, supported by in silico molecular docking simulations.", Life Sci, vol. 338, pp. 122362, 2024.
Muneeb, M., D. M. Abdallah, H. S. El-Abhar, W. Wadie, K. A. Ahmed, and Y. A. S. Fadl, "Antiplatelet therapy as a novel approach in Parkinson's disease: Repositioning Ticagrelor to alleviate rotenone-induced parkinsonism via modulation of ER stress, apoptosis, and autophagy", Neuropharmacology, vol. 269, 2025.
Nasser, S., H. S. El-Abhar, N. El-Maraghy, D. M. Abdallah, W. Wadie, and S. Mansour, Neuroprotective role of mirabegron: Targeting beta-3 adrenergic receptors to alleviate ulcerative colitis-associated cognitive impairment, , 2025.
Abdel-Latif, R. T., H. S. El-Abhar, D. M. Abdallah, I. M. Fawzy, and S. M. Mansour, "Dual inhibition of canonical and noncanonical PAR-1 by SCH79797 mitigates neurodegeneration in 3-NP-induced Huntington's disease: An in vivo and in silico approach", Arch Pharm (Weinheim), vol. 358(3), 2025.
Tourism